Foselutoclax

DB21663InvestigationalSmall molecule

Foselutoclax is a small molecule drug. The usage of the INN stem '-toclax' in the name indicates that Foselutoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Foselutoclax is under investigation... Foselutoclax is under investigation in clinical trial NCT06011798 (Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)).

Mechanism: Pharmacologically active on Bcl-2-like protein 1
Curator reviewed
Formula / weight: C₅₃H₅₉ClF₃N₆O₁₀PS₃ · 1159.69 g/mol (avg)
Code names: UBX1325

Resolves to

Compound

UNIIVT53CL5GESCAS2271269-01-1ChEMBLCHEMBL6068011ChEBI759929PubChem147562879

Structure

InChIKeyFSZILRQCEAUYPL-VQJSHJPSSA-NSMILES

CC(C)N1C(C)=C(C(O)=O)C(=C1C1=CC=C(Cl)C=C1)C1=CC(=CC=C1)N1CCN(CC1)C1=CC=C(NS(=O)(=O)C2=CC(=C(N[C@H](CCN3CCC(CC3)OP(O)(O)=O)CSC3=CC=CC=C3)C=C2)S(=O)(=O)C(F)(F)F)C=C1

Targets

Q07817BCL2L1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Foselutoclax, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account